脱细胞真皮基质相关并发症:比较两种人源基质的植入物乳房再造多中心随机对照试验
两组总体基质相关并发症无统计学差异(4.3% vs 7.1%,p=0.233)。肥胖和胸肌前基质放置是总体基质相关并发症的独立危险因素。
要点
- FlexHD Pliable与AlloDerm RTU的总体基质相关并发症无显著差异(4.3% vs 7.1%,p=0.233)。
- 肥胖(OR 1.14,95%CI 1.05-1.24,p=0.001)与胸肌前放置(OR 4.53,95%CI 1.82-11.3,p=0.001)独立增加并发症风险。
- 证据等级为治疗性I级,支持人脱细胞真皮基质用于植入物乳房再造。
核心结论
- FlexHD Pliable与AlloDerm RTU在植入物乳房再造中基质相关并发症率无显著差异。
- 肥胖和胸肌前基质放置是总体基质相关并发症的独立危险因素。
研究设计与样本
- 1级前瞻性、随机、对照、多中心临床试验,在7个临床中心开展。
- Group A接受FlexHD Pliable(113例患者,187例乳房再造),Group B接受AlloDerm RTU(117例患者,197例乳房再造)。
- 平均随访10.7±3.2个月。
主要发现
- 两组总体基质相关并发症无统计学差异(4.3% versus 7.1%,p=0.233)。
- 肥胖与总体基质相关并发症风险增加独立相关(OR 1.14;95%CI 1.05-1.24;p=0.001)。
- 胸肌前基质放置与总体基质相关并发症风险增加独立相关(OR 4.53;95%CI 1.82-11.3;p=0.001)。
- 两组患者人口学特征、适应证、合并症和再造方式无显著差异。
临床怎么用
- 两种常用人脱细胞真皮基质在植入物乳房再造中均可使用,并发症率无显著差异。
- 对肥胖患者或计划胸肌前放置基质者应加强并发症风险告知与监测。
局限性
- 平均随访时间较短(10.7±3.2个月),长期并发症未评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Implant-based breast reconstruction accounts for the vast majority of breast reconstruction procedures and is commonly performed with human acellular dermal matrix. There is no consensus as to the optimal human acellular dermal matrix preparation, and high-quality evidence concerning comparative effectiveness is lacking. This study is the first prospective, multicenter, randomized controlled clinical trial to compare human acellular dermal matrix-related complications of the two most commonly used human acellular dermal matrices in implant-based breast reconstruction. The authors hypothesize that there will be no difference in infection, seroma, and reconstructive failure between FlexHD Pliable and AlloDerm RTU. METHODS: The authors conducted a Level 1 prospective, randomized, controlled, multicenter clinical trial to assess complications associated with the use of two human acellular dermal matrices in immediate postmastectomy implant-based breast reconstruction across seven clinical sites. Group A patients received FlexHD Pliable (113 patients with 187 breast reconstructions), and group B patients received AlloDerm RTU (117 patients with 197 breast reconstructions). RESULTS: There was no significant difference with respect to patient demographics, indications, comorbidities, and reconstruction approach between groups. Mean follow-up time was 10.7 ± 3.2 months. There was no statistical difference in the overall matrix-related complications between groups A and B (4.3 percent versus 7.1 percent, p = 0.233). Obesity (OR, 1.14; 95 percent CI, 1.05 to 1.24; p = 0.001) and prepectoral placement of matrix (OR, 4.53; 95 percent CI, 1.82 to 11.3; p = 0.001) were independently associated with greater risks of overall matrix-related complications. CONCLUSION: This work supports the use of human acellular dermal matrices in implant-based breast reconstruction and demonstrates no significant difference in matrix-related complication rates between FlexHD Pliable and AlloDerm RTU. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, I.
引用
- Broyles JM, Liao EC, Kim J, et al. Acellular Dermal Matrix-Associated Complications in Implant-Based Breast Reconstruction: A Multicenter, Prospective, Randomized Controlled Clinical Trial Comparing Two Human Tissues. Plast Reconstr Surg. 2021. PMID: 33877063. doi:10.1097/PRS.0000000000008194
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。